Key facts
- Bacchus Bio innovation’s last known valuation is $63.2M (Apr 2025).
- It has raised $27.9M; the latest was Later Stage VC in Oct 2025.
- Notable investors include Mizuho Bank, Alliance Forum Foundation, DEFTA Partners, Idemitsu Kosan, JGC Holdings — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Bacchus Bio innovation
- ·The full record, as it builds
Funding rounds
No funding rounds for Bacchus Bio innovation are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Bacchus Bio innovation
Operator of a biotechnology platform intended to solve environmental problems through sustainable social contributions. The company's platform offers services for environmental challenges using synthetic biology and advanced technologies, enabling the healthcare sector to contribute to a sustainable future through its integrated bio-foundry services.
- Sector
- Healthcare
- HQ
- Kobe, Japan
- Founded
- 2020
- Employees
- 90
- Website
- b2i.co.jp/
- Ownership
- Privately Held (backing)
Bacchus Bio innovation doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bacchus Bio innovation shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bacchus Bio innovation in its N-PORT filings yet. We sweep new filings monthly.